Scientific Organizers:
William E. Dowling, NIAID, National Institutes of Health, USA
Thomas W. Geisbert, University of Texas Medical Branch, USA

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Viral Hemorrhagic Fevers (VHF) are caused by a disparate group of viruses from four different virus families – Arenaviruses, Bunyaviruses, Filoviruses and Flaviviruses. These viruses have a substantial public health impact with few effective vaccines or antivirals available. Although their structures, vectors and replication cycles are very different, there are common pathogenic features between them. The meeting is designed to bring together the research communities around these individual viral families, to explore common pathways and mechanisms employed by the viruses, to discuss current medical countermeasures, and to foster collaborations. The specific aims of the conference are to:

1) Discuss the methods employed by hemorrhagic fever viruses to subvert host innate immune responses;
2) Assess the mechanisms causing endothelial dysfunction and coagulopathy that are hallmarks of VHF disease;
3) Look at the contributions of host genetics in disease progression;
4) Describe the state of the art in diagnostics;
5) Present data on promising candidate vaccines and therapeutics.

This symposium will occupy a unique niche as there is not a current scientific conference which brings these communities together in a focused manner.

Session Topics:
• Innate Immune Evasion
• Host Genetics
• Endothelial Dysfunction and Coagulopathy
• Diagnostics
• Vaccines I & II
• Therapeutics I & II
plus two workshops elaborating on plenary session themes

Global Health Travel Award Application Deadline: July 19, 2016
Scholarship Application & Discounted Abstract Deadline: August 4, 2016
Abstract Deadline: September 12, 2016
Discounted Registration Deadline: October 4, 2016

Note: Scholarships and Underrepresented Trainee Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted. Global Travel Awards are for investigators from low and middle-income countries

Meeting Hashtag: #KShfv
www.keystonesymposia.org/16S3
For the most up-to-date details, visit www.keystonesymposia.org/17S3.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Hemorrhagic Fever Viruses (S3)
December 4-8, 2016 • Hilton Santa Fe Historic Plaza Hotel • Santa Fe, New Mexico, USA
Scientific Organizers: William E. Dowling and Thomas W. Geisbert
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

* Session Chair † Invited but not yet accepted Program current as of June 25, 2019. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit www.keystonesymposia.org/17S3.
John H. Connor, Boston University School of Medicine, USA
Short Talk: Real-Time Visualization of Individual Hemorrhagic Fever Virions in Solution

Frederick Holtsberg, Integrated Biotherapeutics, USA
Short Talk

Poster Session 2

WEDNESDAY, DECEMBER 7

Vaccines I
*Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA
Michael Egan, Profectus Biosciences, USA
Filoivirus rVSV Vaccines
Sheri Dubey, Merck & Co., Inc., USA
Clinical Development of a Recombinant Ebola Vaccine in the Midst of an Unprecedented Outbreak
Heinz Feldmann, Rocky Mountain Laboratories, USA
Lassa rVSV Vaccines
Andrea Marzi, NIAID, National Institutes of Health, USA
Short Talk: Efficacy of VSV-EBOV Post-Exposure Treatment in Rhesus Macaques Infected with EBOV-Makona
Farshad Guirakhoo, GeoVax, Inc., USA
Short Talk: MVA-VLP Platform for Development of a Single Dose Tetravalent Vaccine against Hemorrhagic Fever Viruses
Igor Lukashevich, University of Louisville, USA
Short Talk: Reassortant ML29 Vaccine Platform to Control Lassa Fever in West Africa

Vaccines II
*Heinz Feldmann, Rocky Mountain Laboratories, USA
Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
The Live Attenuated Dengue Vaccines TV003 and TV005 Completely Protect Against DENV-2 Infection in a Controlled Dengue Human Challenge Model
Shinji Makino, University of Texas Medical Branch, USA
Development of a Single-Cycle Replicable Rift Valley Fever Virus Vaccine
Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA
Clinical Assessment of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome (HFRS)
Courtney Brooke Woolsey, University of Texas Medical Branch, USA
Short Talk: A Recombinant Vesicular Stomatitis Virus-Based Vaccine Mediates Post-Exposure Protection against Marburg Virus Angola in Rhesus Macaques

Posters Session 3

THURSDAY, DECEMBER 8

Therapeutics I
*Andrea Marzi, NIAID, National Institutes of Health, USA
Larry Zeitlin, Mapp Biopharmaceutical, Inc., USA
Junin and Filovirus mAb Therapeutics

Thomas W. Geisbert, University of Texas Medical Branch, USA
Filoivirus siRNA Therapeutics
Luis M. Branco, Zaigen Labs, LLC, USA
Lassa Virus Human Monoclonal Antibody Therapeutics
Eric Bergeron, Centers for Disease Control and Prevention, USA
Short Talk: Antiviral Activity and Mechanism of Action of Site-1 Protease (S1P) Inhibitor on Crimean-Congo Hemorrhagic Fever Virus
Zachary Bornholdt, Mapp Biopharmaceutical, USA
The Structure-Based Design of a Pan-ebolavirus Immunotherapeutic Cocktail
Anna Z. Wec, Adimab LLC, USA
Short Talk: Bispecific Antibodies Targeting the Intracellular Virus-Receptor Interaction Provide Broad in vivo Protection Against Ebolaviruses
Bronwyn M. Gunn, Massachusetts General Hospital, USA
Short Talk: Antibody Fc-Effector Functionality Predicts Monoclonal Antibody-Mediated Post-Exposure Protection against Ebola Virus Challenge

Therapeutics II
*Chad E. Mire, Galveston National Laboratory, USA
Brian Gowen, Utah State University, USA
Prospects for Treatment of Severe Arenavirus and Bunyavirus Infections
M. Javad Aman, Integrated Biotherapeutics, Inc., USA
Short Talk: Cross-Protection Against Ebolaviruses with Vaccine Elicited Broadly Neutralizing Monoclonal Antibody Cocktails: Evidence for Cooperative Neutralization
Travis K. Warren, US Army Medical Research Institute of Infectious Diseases, USA
In vivo Efficacy of BCX4430 Against Ebola Virus
John Misasi, NIAID, National Institutes of Health, USA
Protective Monotherapy Against Ebola Infection: Structure and Molecular Basis of Potent Neutralization
Ami Patel, Wistar Institute, USA
Short Talk: DNA-Delivery of Monoclonal Antibodies (DMAbs) as an Alternative, in vivo mAb Delivery Platform against Ebola Virus Infection

FRIDAY, DECEMBER 9

Departure